UA75647C2 - Mercaptoacetylamide derivatives, a process for their preparation, pharmaceutical composition based thereon and a process for preparation of intermediate compound - Google Patents

Mercaptoacetylamide derivatives, a process for their preparation, pharmaceutical composition based thereon and a process for preparation of intermediate compound Download PDF

Info

Publication number: UA75647C2
Authority: UA; Ukraine
Prior art keywords: aryl; alkyl; compound; formula; compound according
Prior art date: 2001-04-12

Application number

UA20031110184A

Other languages

English (en)

Ukrainian (uk)

Inventor

Garya Flynn

Roger Koehl

Ann Anderson

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-12

Filing date

2002-03-04

Publication date

2006-05-15

2002-03-04 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2002-04-03 Priority claimed from PCT/EP2002/003668 external-priority patent/WO2002083671A1/en

2006-05-15 Publication of UA75647C2 publication Critical patent/UA75647C2/uk

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 98
238000000034 method Methods 0.000 title claims abstract description 31
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
GYXHHICIFZSKKZ-UHFFFAOYSA-N 2-sulfanylacetamide Chemical class NC(=O)CS GYXHHICIFZSKKZ-UHFFFAOYSA-N 0.000 title abstract description 3
238000002360 preparation method Methods 0.000 title description 15
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims abstract description 11
206010019280 Heart failures Diseases 0.000 claims abstract description 10
206010007559 Cardiac failure congestive Diseases 0.000 claims abstract description 7
206010020772 Hypertension Diseases 0.000 claims abstract description 3
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims abstract 2
-1 methylenedioxy Chemical group 0.000 claims description 41
125000003118 aryl group Chemical group 0.000 claims description 34
239000001257 hydrogen Substances 0.000 claims description 23
229910052739 hydrogen Inorganic materials 0.000 claims description 23
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
PVQATPQSBYNMGE-UHFFFAOYSA-N [benzhydryloxy(phenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)OC(C=1C=CC=CC=1)C1=CC=CC=C1 PVQATPQSBYNMGE-UHFFFAOYSA-N 0.000 claims description 12
238000006243 chemical reaction Methods 0.000 claims description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
125000004432 carbon atom Chemical group C* 0.000 claims description 11
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims description 10
229910052799 carbon Inorganic materials 0.000 claims description 10
201000010099 disease Diseases 0.000 claims description 10
150000002431 hydrogen Chemical class 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 8
125000002252 acyl group Chemical group 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 7
230000002401 inhibitory effect Effects 0.000 claims description 7
229910052736 halogen Inorganic materials 0.000 claims description 5
150000002367 halogens Chemical class 0.000 claims description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
125000000217 alkyl group Chemical group 0.000 claims description 3
229910052731 fluorine Inorganic materials 0.000 claims description 3
125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
208000024172 Cardiovascular disease Diseases 0.000 claims 1
102000005593 Endopeptidases Human genes 0.000 claims 1
108010059378 Endopeptidases Proteins 0.000 claims 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
230000007935 neutral effect Effects 0.000 claims 1
102000003729 Neprilysin Human genes 0.000 abstract description 12
108090000028 Neprilysin Proteins 0.000 abstract description 12
230000005764 inhibitory process Effects 0.000 abstract description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
239000000203 mixture Substances 0.000 description 17
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 15
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
239000000010 aprotic solvent Substances 0.000 description 11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
102100030988 Angiotensin-converting enzyme Human genes 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
229910052740 iodine Inorganic materials 0.000 description 9
239000000546 pharmaceutical excipient Substances 0.000 description 9
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
239000002585 base Substances 0.000 description 7
239000000243 solution Substances 0.000 description 7
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
229950001336 bromamide Drugs 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
239000004480 active ingredient Substances 0.000 description 5
239000003826 tablet Substances 0.000 description 5
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 4
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 4
102400000345 Angiotensin-2 Human genes 0.000 description 4
101800000733 Angiotensin-2 Proteins 0.000 description 4
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
150000001299 aldehydes Chemical class 0.000 description 4
229960002478 aldosterone Drugs 0.000 description 4
229950006323 angiotensin ii Drugs 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
150000002081 enamines Chemical class 0.000 description 4
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
239000000047 product Substances 0.000 description 4
239000011734 sodium Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical class COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
229910000024 caesium carbonate Inorganic materials 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
239000012043 crude product Substances 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
229940126601 medicinal product Drugs 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 3
KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 3
230000004044 response Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
CMIRWXFQPVROKZ-UHFFFAOYSA-N 5h-2-benzazepine-4-carboxylic acid Chemical compound C1C(C(=O)O)=CN=CC2=CC=CC=C21 CMIRWXFQPVROKZ-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
102400000344 Angiotensin-1 Human genes 0.000 description 2
101800000734 Angiotensin-1 Proteins 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
101800004538 Bradykinin Proteins 0.000 description 2
102400000967 Bradykinin Human genes 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
208000004880 Polyuria Diseases 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
208000001647 Renal Insufficiency Diseases 0.000 description 2
108090000783 Renin Proteins 0.000 description 2
102100028255 Renin Human genes 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
210000002072 atrial myocyte Anatomy 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
230000007882 cirrhosis Effects 0.000 description 2
208000019425 cirrhosis of liver Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
230000035619 diuresis Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
125000001033 ether group Chemical group 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
150000002430 hydrocarbons Chemical group 0.000 description 2
150000004679 hydroxides Chemical class 0.000 description 2
125000004356 hydroxy functional group Chemical group O* 0.000 description 2
230000001077 hypotensive effect Effects 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
150000004702 methyl esters Chemical class 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
239000012299 nitrogen atmosphere Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
125000005543 phthalimide group Chemical group 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
230000012495 positive regulation of renal sodium excretion Effects 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000006722 reduction reaction Methods 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
239000007858 starting material Substances 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
125000006168 tricyclic group Chemical group 0.000 description 2
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 1
125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
GDSOQCSYONDNAJ-UHFFFAOYSA-N 2-thiophen-2-ylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1=CC=CS1 GDSOQCSYONDNAJ-UHFFFAOYSA-N 0.000 description 1
ICBQXEWYZVQCFH-UHFFFAOYSA-N 3-(4-bromoanilino)-n,n-dimethylpropanamide Chemical compound CN(C)C(=O)CCNC1=CC=C(Br)C=C1 ICBQXEWYZVQCFH-UHFFFAOYSA-N 0.000 description 1
SFWWGMKXCYLZEG-UHFFFAOYSA-N 3-methylmorpholine Chemical compound CC1COCCN1 SFWWGMKXCYLZEG-UHFFFAOYSA-N 0.000 description 1
125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
125000005274 4-hydroxybenzoic acid group Chemical group 0.000 description 1
WLPPCFGXINTUNZ-UHFFFAOYSA-N 5h-1-benzazepine-4-carboxylic acid Chemical compound C1C(C(=O)O)=CC=NC2=CC=CC=C21 WLPPCFGXINTUNZ-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
101500020117 Aedes aegypti Sialokinin Proteins 0.000 description 1
102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
101800001288 Atrial natriuretic factor Proteins 0.000 description 1
102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
206010007572 Cardiac hypertrophy Diseases 0.000 description 1
208000006029 Cardiomegaly Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
244000223760 Cinnamomum zeylanicum Species 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
102000004860 Dipeptidases Human genes 0.000 description 1
108090001081 Dipeptidases Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
238000005727 Friedel-Crafts reaction Methods 0.000 description 1
241001547860 Gaya Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
244000246386 Mentha pulegium Species 0.000 description 1
235000016257 Mentha pulegium Nutrition 0.000 description 1
235000004357 Mentha x piperita Nutrition 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001494479 Pecora Species 0.000 description 1
LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
238000006859 Swern oxidation reaction Methods 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
230000009102 absorption Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
238000007171 acid catalysis Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
210000004404 adrenal cortex Anatomy 0.000 description 1
101150118680 aflR gene Proteins 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
150000004982 aromatic amines Chemical class 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000001746 atrial effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
UIJGNTRUPZPVNG-UHFFFAOYSA-N benzenecarbothioic s-acid Chemical class SC(=O)C1=CC=CC=C1 UIJGNTRUPZPVNG-UHFFFAOYSA-N 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000010170 biological method Methods 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000012267 brine Substances 0.000 description 1
SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical class OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
OQROAIRCEOBYJA-UHFFFAOYSA-N bromodiphenylmethane Chemical compound C=1C=CC=CC=1C(Br)C1=CC=CC=C1 OQROAIRCEOBYJA-UHFFFAOYSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000015218 chewing gum Nutrition 0.000 description 1
235000017803 cinnamon Nutrition 0.000 description 1
230000004087 circulation Effects 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000010586 diagram Methods 0.000 description 1
ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
230000010339 dilation Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
125000000532 dioxanyl group Chemical group 0.000 description 1
CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical compound C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
DUYAAUVXQSMXQP-UHFFFAOYSA-N ethanethioic S-acid Chemical compound CC(S)=O DUYAAUVXQSMXQP-UHFFFAOYSA-N 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000010855 food raising agent Nutrition 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
230000004217 heart function Effects 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
235000001050 hortel pimenta Nutrition 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
230000006872 improvement Effects 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000011630 iodine Substances 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
239000008101 lactose Substances 0.000 description 1
XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960001047 methyl salicylate Drugs 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
ULWOJODHECIZAU-UHFFFAOYSA-N n,n-diethylpropan-2-amine Chemical compound CCN(CC)C(C)C ULWOJODHECIZAU-UHFFFAOYSA-N 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000002644 neurohormonal effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000007968 orange flavor Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
125000001151 peptidyl group Chemical group 0.000 description 1
230000036513 peripheral conductance Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000003586 protic polar solvent Substances 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000009103 reabsorption Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
206010038464 renal hypertension Diseases 0.000 description 1
125000006413 ring segment Chemical group 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
230000001235 sensitizing effect Effects 0.000 description 1
239000004208 shellac Substances 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000011916 stereoselective reduction Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Heart & Thoracic Surgery (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

UA20031110184A 2001-04-12 2002-03-04 Mercaptoacetylamide derivatives, a process for their preparation, pharmaceutical composition based thereon and a process for preparation of intermediate compound UA75647C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28330501P	2001-04-12	2001-04-12
PCT/EP2002/003668 WO2002083671A1 (en)	2001-04-12	2002-04-03	Mercaptoacetylamide derivatives, a process for their preparation and their use

Publications (1)

Publication Number	Publication Date
UA75647C2 true UA75647C2 (en)	2006-05-15

Family

ID=23085405

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20031110184A UA75647C2 (en)	2001-04-12	2002-03-04	Mercaptoacetylamide derivatives, a process for their preparation, pharmaceutical composition based thereon and a process for preparation of intermediate compound

Country Status (17)

Country	Link
US (1)	US6602866B2 (zh)
KR (1)	KR100910929B1 (zh)
AR (1)	AR034307A1 (zh)
CR (1)	CR7074A (zh)
DK (1)	DK1381605T3 (zh)
EC (1)	ECSP034782A (zh)
GB (1)	GB0119305D0 (zh)
GT (1)	GT200200069A (zh)
IL (1)	IL158289A (zh)
MY (1)	MY128226A (zh)
PE (1)	PE20021079A1 (zh)
RS (1)	RS50919B (zh)
TN (1)	TNSN03083A1 (zh)
TW (1)	TWI319764B (zh)
UA (1)	UA75647C2 (zh)
UY (1)	UY27255A1 (zh)
ZA (1)	ZA200307096B (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1481960A4 (en) *	2002-02-04	2005-04-06	Kaneka Corp	PROCESS FOR OBTAINING OPTICALLY ACTIVE 2-HALOGENO-CARBOXYLIC ACIDS
TW200838501A (en)	2007-02-02	2008-10-01	Theravance Inc	Dual-acting antihypertensive agents
TWI448284B (zh) *	2007-04-24	2014-08-11	Theravance Inc	雙效抗高血壓劑
TWI406850B (zh) *	2007-06-05	2013-09-01	Theravance Inc	雙效苯并咪唑抗高血壓劑
US7834041B2 (en) *	2007-09-07	2010-11-16	Theravance, Inc.	Dual-acting antihypertensive agents
EP2234608A2 (en)	2007-12-11	2010-10-06	Viamet Pharmaceuticals, Inc.	Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
CA2705921A1 (en)	2007-12-11	2009-06-18	Theravance, Inc.	Dual-acting benzoimidazole derivatives and their use as antihypertensive agents
EP2297113A1 (en)	2008-04-29	2011-03-23	Theravance, Inc.	Dual-acting antihypertensive agents
US7863309B2 (en)	2008-07-24	2011-01-04	Theravance, Inc.	Dual-acting antihypertensive agents
WO2011005674A1 (en)	2009-07-07	2011-01-13	Theravance, Inc.	Dual-acting pyrazole antihypertensive agents
JP2012533626A (ja)	2009-07-22	2012-12-27	セラヴァンス，インコーポレーテッド	二重作用オキサゾール降圧剤
EP2526095A1 (en)	2010-01-19	2012-11-28	Theravance, Inc.	Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
EP2651900B1 (en)	2010-12-15	2015-08-19	Theravance Biopharma R&D IP, LLC	Neprilysin inhibitors
CA2817368C (en)	2010-12-15	2019-12-31	Theravance, Inc.	Neprilysin inhibitors
US8449890B2 (en)	2011-02-17	2013-05-28	Theravance, Inc.	Neprilysin inhibitors
EP2675795B1 (en)	2011-02-17	2016-04-20	Theravance Biopharma R&D IP, LLC	Substituted aminobutyric derivatives as neprilysin inhibitors
EP2714648B1 (en)	2011-05-31	2017-08-16	Theravance Biopharma R&D IP, LLC	Neprilysin inhibitors
JP5959075B2 (ja)	2011-05-31	2016-08-02	セラヴァンスバイオファーマアール＆ディーアイピー，エルエルシー	ネプリライシン阻害剤
EP2714662B1 (en)	2011-05-31	2017-10-11	Theravance Biopharma R&D IP, LLC	Neprilysin inhibitors
TWI560172B (en)	2011-11-02	2016-12-01	Theravance Biopharma R&D Ip Llc	Neprilysin inhibitors
WO2013181332A1 (en)	2012-05-31	2013-12-05	Theravance, Inc.	Nitric oxide donor neprilysin inhibitors
WO2013184898A1 (en)	2012-06-08	2013-12-12	Theravance, Inc.	Neprilysin inhibitors
AU2013271537B2 (en)	2012-06-08	2017-05-11	Theravance Biopharma R&D Ip, Llc	Neprilysin inhibitors
JP6092390B2 (ja)	2012-08-08	2017-03-08	セラヴァンスバイオファーマアール＆ディーアイピー，エルエルシー	ネプリライシン阻害剤
HUE034210T2 (hu)	2013-03-05	2018-02-28	Theravance Biopharma R&D Ip Llc	Neprilizininhibitorok
US9585882B2 (en)	2014-01-30	2017-03-07	Theravance Biopharma R&D Ip, Llc	Neprilysin inhibitors
SG11201605965UA (en)	2014-01-30	2016-08-30	Theravance Biopharma R&D Ip Llc	Neprilysin inhibitors
KR102640906B1 (ko)	2015-02-11	2024-02-27	세라밴스 바이오파마 알앤디 아이피, 엘엘씨	네프릴리신 저해제로서 (2s,4r)-5-(5''-클로로-2''-플루오로비페닐-4-일)-4-(에톡시옥살릴아미노)-2-히드록시메틸-2-메틸펜타노익산
EP3259255B1 (en)	2015-02-19	2020-10-21	Theravance Biopharma R&D IP, LLC	(2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
MX2018010727A (es)	2016-03-08	2019-01-24	Theravance Biopharma R&D Ip Llc	Acido (2s,4r)-5-(5'-cloro-2'-fluoro-[1,1'-bifenil]-4-il)-2-(etoxim etil)-4-(3-hidroxiisoxazol-5-carboxamido)-2-metilpentanoico cristalino, y sus usos.

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3334095A (en)	1965-02-16	1967-08-01	Sandoz Ag	Novel pyrrolo-oxazines and pyrrolo-oxazoles
US3334091A (en)	1965-03-25	1967-08-01	Sandoz Ag	Sedatives
GB1525845A (en)	1976-07-30	1978-09-20	Ucb Sa	1,2,4,5-tetrahydro-3h-2-benzazepin-3-ones
IE50839B1 (en)	1980-02-26	1986-07-23	Wyeth John & Brother Ltd	Novel processes for preparing proline derivatives and analogous compounds
EP0042100A1 (de)	1980-06-13	1981-12-23	F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft	Pyrazolopyridazin-Derivate, Zwischenprodukte und Verfahren zu deren Herstellung, sowie diese enthaltende Arzneimittel
US4320057A (en)	1980-06-23	1982-03-16	American Home Products Corporation	Aryl--pyrrolo--thiazepin--diones and aryl--piperidino--thiazepin--diones
US4415496A (en)	1981-03-23	1983-11-15	Merck & Co., Inc.	Bicyclic lactams
GB2128984B (en)	1982-05-12	1985-05-22	Hoffmann La Roche	Diaza-bicyclic compounds
NZ204130A (en)	1982-05-12	1986-03-14	Hoffmann La Roche	Bicyclic heterocyclic compounds and pharmaceutical compositions
US4552889A (en)	1983-06-09	1985-11-12	Eli Lilly And Company	3-Mercaptomethyl-2-oxo-1-pyrrolidine acetic acids and use for hypertension
US4692438A (en)	1984-08-24	1987-09-08	Hoffmann-La Roche Inc.	Pyridazo-diazepines, diazocines, and -triazepines having anti-hypertensive activity
US4584294A (en)	1984-11-07	1986-04-22	Merck & Co., Inc.	Fused tricyclic lactams as angiotensin converting enzyme inhibitors and as antihypertensive agents
ZA863170B (en)	1985-04-30	1987-12-30	Lilly Co Eli	7-substituted bicyclic pyrazolidinones
US4973585A (en)	1986-06-13	1990-11-27	Merrell Dow Pharmaceuticals	Tricyclic lactams active as antihypertensive agents
ZA874106B (en)	1986-06-13	1987-12-08	Merrell Dow Pharmaceuticals Inc.	Novel antihypertensive agent
ZA874107B (zh)	1986-06-13	1987-12-09
GB8629875D0 (en)	1986-12-15	1987-01-28	Hoffmann La Roche	Pyridazodiazepine derivatives
US4824832A (en)	1987-12-30	1989-04-25	Merrell Dow Pharmaceuticals Inc.	Sulfhydryl containing tricyclic lactams and their pharmacological methods of use
GB8926512D0 (en)	1989-11-23	1990-01-10	Pfizer Ltd	Therapeutic agents
AU7168091A (en)	1989-12-22	1991-07-24	Schering Corporation	Mercaptocycloacyl aminoacid endopeptidase inhibitors
US5430145A (en) *	1990-10-18	1995-07-04	Merrell Dow Pharmaceuticals Inc.	Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
CA2053340C (en)	1990-10-18	2002-04-02	Timothy P. Burkholder	Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5491143A (en)	1990-10-18	1996-02-13	Merrell Dow Pharmaceuticals Inc.	Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ACE
DK0492369T3 (da)	1990-12-21	1997-10-13	Merrell Pharma Inc	Hidtil ukendte tricycliske amino- og nitro-forbindelser med ACE-hæmmende virkning
US5208230A (en)	1990-12-21	1993-05-04	Merrell Dow Pharmaceuticals	Amino and nitro containing tricyclic compounds useful as inhibitors of ACE
FR2679564A1 (fr)	1991-07-23	1993-01-29	Inst Nat Sante Rech Med	Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent.
EP0605589A1 (en)	1991-09-16	1994-07-13	Schering Corporation	Pharmaceutical compositions comprising natriuretic peptides or neutral endopeptidase inhibitors for treating or preventing myointimal proliferation
DK0534363T3 (da)	1991-09-27	1997-09-22	Merrell Pharma Inc	2-substituerede indan-2-mercaptoacetylamid-forbindelse med inhiberende virkning på enkephalinase og ACE.
AU657793B2 (en)	1991-09-27	1995-03-23	Merrell Pharmaceuticals Inc.	Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
AU668707B2 (en)	1992-02-14	1996-05-16	Merrell Pharmaceuticals Inc.	Aminoacetylmercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ACE
WO1993023403A1 (en)	1992-05-15	1993-11-25	Merrell Dow Pharmaceuticals Inc.	NOVEL MERCAPTOACETYLAMIDO PYRIDAZO[1,2]PYRIDAZINE, PYRAZOLO[1,2]PYRIDAZINE, PYRIDAZO[1,2-a][1,2]DIAZEPINE AND PYRAZOLO[1,2-a][1,2]DIAZEPINE DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE
RU2124503C1 (ru)	1992-05-18	1999-01-10	И.Р.Сквибб энд Санз, Инк.	Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция
US5238932A (en)	1992-05-20	1993-08-24	Merrell Dow Pharmaceuticals Inc.	Mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase
US5679671A (en) *	1993-06-11	1997-10-21	Eisai Co., Ltd.	Amino acid derivative
US5525723A (en)	1993-11-18	1996-06-11	Bristol-Myers Squibb Co.	Compounds containing a fused multiple ring lactam
DE69416873T2 (de) *	1994-02-14	1999-07-29	Merrell Pharmaceuticals Inc., Cincinnati, Ohio	Mercaptoacetylamid disulfidderivate als enkephalinase und ace inhibitoren
DK0751774T3 (da) *	1994-03-24	2003-12-08	Merrell Pharma Inc	Hypocholesterolæmiske mercaptoacetylamiddisulfid-derivater

2001
- 2001-08-08 GB GBGB0119305.1A patent/GB0119305D0/en not_active Ceased
2002
- 2002-03-04 UA UA20031110184A patent/UA75647C2/uk unknown
- 2002-04-03 RS YUP-787/03A patent/RS50919B/sr unknown
- 2002-04-03 DK DK02732549T patent/DK1381605T3/da active
- 2002-04-03 KR KR1020037013181A patent/KR100910929B1/ko not_active IP Right Cessation
- 2002-04-08 US US10/118,179 patent/US6602866B2/en not_active Expired - Lifetime
- 2002-04-10 TW TW091107133A patent/TWI319764B/zh not_active IP Right Cessation
- 2002-04-10 UY UY27255A patent/UY27255A1/es not_active Application Discontinuation
- 2002-04-10 PE PE2002000294A patent/PE20021079A1/es not_active Application Discontinuation
- 2002-04-10 GT GT200200069A patent/GT200200069A/es unknown
- 2002-04-10 AR ARP020101321A patent/AR034307A1/es active IP Right Grant
- 2002-04-10 MY MYPI20021326A patent/MY128226A/en unknown
2003
- 2003-07-08 TN TNPCT/EP2002/003668A patent/TNSN03083A1/en unknown
- 2003-09-11 ZA ZA200307096A patent/ZA200307096B/en unknown
- 2003-09-12 CR CR7074A patent/CR7074A/es not_active Application Discontinuation
- 2003-09-26 EC EC2003004782A patent/ECSP034782A/es unknown
- 2003-10-07 IL IL158289A patent/IL158289A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
MY128226A (en)	2007-01-31
GB0119305D0 (en)	2001-10-03
RS50919B (sr)	2010-08-31
KR20040008153A (ko)	2004-01-28
TWI319764B (en)	2010-01-21
US20020193589A1 (en)	2002-12-19
DK1381605T3 (da)	2005-05-09
AR034307A1 (es)	2004-02-18
UY27255A1 (es)	2002-07-31
TNSN03083A1 (en)	2005-12-23
IL158289A (en)	2010-11-30
GT200200069A (es)	2002-12-17
US6602866B2 (en)	2003-08-05
KR100910929B1 (ko)	2009-08-06
YU78703A (sh)	2006-05-25
ECSP034782A (es)	2003-12-01
PE20021079A1 (es)	2003-02-19
CR7074A (es)	2007-12-04
ZA200307096B (en)	2004-09-06

Publication	Publication Date	Title
UA75647C2 (en)	2006-05-15	Mercaptoacetylamide derivatives, a process for their preparation, pharmaceutical composition based thereon and a process for preparation of intermediate compound
DE69333062T2 (de)	2004-05-06	4-mercaptoacetylamino-[2]benzazepinon(3)- derivate, und verwendung als enkephalinase-inhibitoren
KR100271239B1 (ko)	2001-02-01	엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 2-치환인단-2-메르캅토아세틸아미드 유도체
DE69216026T2 (de)	1997-07-17	Karboxyalkylsubstituierte Enkephalinase und ACE-Hemmer
DE69329701T2 (de)	2001-05-10	Mercaptoacetylamid substituiertes bizyclisches laktam zur verwendung als enkephalinase und ace-hemmer
DE69128516T2 (de)	1998-07-23	Neue Mercaptoacetylamid-Derivate zur Verwendung als Enkephalinase- und ACE-Hemmer
KR100220879B1 (ko)	2000-03-15	안지오텐신 전환 효소 억제제로서 유용한 신규 아미노 및 니트로 함유 트리시클릭 화합물
IL112606A (en)	2001-03-19	History of Mercaptoacetylamide - 1, 3, 4, 5 - Tetra - Hydro - Benzo [C] Azpine - 3 and disulfide, process for their preparation and pharmaceutical preparations containing them
IE56230B1 (en)	1991-05-22	New derivatives of tricyclic aminoacids,processes for their preparation,agents containing these compounds and their use,and new bicyclic aminoacids as intermediates and processes for their preparation
DE69326474T2 (de)	2000-02-17	Neue 2-substituierte tricyclische derivate von indan-2-mercaptoacetylamid verwendbar als enkephalinase inhibitoren
RU2286346C2 (ru)	2006-10-27	Производные меркаптоацетиламида, способ их получения, фармацевтическая композиция на их основе, способ ее получения и способ лечения сердечно-сосудистого болезненного состояния
AU2002304804A1 (en)	2003-04-10	Mercaptoacetylamide derivatives, a process for their preparation and their use
JP3310687B2 (ja)	2002-08-05	キノン誘導体
US5491143A (en)	1996-02-13	Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ACE
JPH07509441A (ja)	1995-10-19	Ｎ−（メルカプトアシル）アミノ酸と、その製造方法と、その治療での使用と、それを含む医薬組成物
US5508411A (en)	1996-04-16	Process for preparing (S)-1-[2(S)-(1,3-dihyrdro-1,3-dioxo-isoindo-2-yl)-1-oxo-3-phenylpropyl]-1,2,3,4,-tetrahydro-2-pyridine-carboxylic acid methyl ester
HU208121B (en)	1993-08-30	Process for producing perhydrothiazepine and perhydroazepine derivatives and pharmaceutical compositions comprising such compounds as active ingredient
TW200485B (zh)	1993-02-21